Alfred Garfall, MD
Enriched profileAssociate Professor of Medicine (Hematology-Oncology); Multiple Myeloma Section Chief; Director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania · University of Pennsylvania
Alfred Garfall is Associate Professor of Medicine (Hematology-Oncology); Multiple Myeloma Section Chief; Director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania at University of Pennsylvania. OpenAlex indexes 312 publications with 12,299 citations (h-index 42); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Alfred L. Garfall, MD, is Associate Professor of Medicine (Hematology-Oncology) at University of Pennsylvania / Hospital of the University of Pennsylvania (Perelman School of Medicine, Abramson Cancer Center). The public record shows 312 publications with 12,299 citations (h-index 42), centered on Multiple Myeloma. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 12 companies, 2 NIH-funded awards (2020–2026).
- Most recent indexed publication: 2026 · The New England journal of medicine
- Top research focus: Multiple Myeloma
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- CAR-T Cell Therapy for Desensitization in Kidney Transplantation
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Limited-duration Teclistamab
Sponsor: Abramson Cancer Center at Penn Medicine
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Sponsor: Medical College of Wisconsin
Industry payments
Updated 16 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year202518 payments$12,609openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.7%Thalidomide Analog71.7%Lenalidomide48%Revlimid28%Pomalyst24%Part D<11 patientsDermatology
13.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.9%Acyclovir100%Part D≥15 patientsAnti-infectives
7.5%Short-acting sulfonamides7.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation
University of Pennsylvania
FY2026$4,316,508U01AI163087 - Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation
University of Pennsylvania
FY2025$4,303,502U01AI163087 - Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation
University of Pennsylvania
FY2024$3,825,129U01AI163087
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.
The New England journal of medicine
Clinical Trial2026 - Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.
The Journal of experimental medicine
Article2026
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/alfred-garfall-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Alfred-Garfall
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/AlGarfall
- LinkedIn
linkedin.com/in/alfred-garfall-8218474
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/PennMDForum/status/1087462917128228864
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Editorial & leadership roles
journal and society appointments- Multiple Myeloma Section Chief
Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Director
Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Attending Physician
Hospital of the University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Awards & honors
honors on the public record- Leukemia & Lymphoma Society (Blood Cancer United) Academic Clinical Trial (ACT) grant
multi-year research commitment for a study of limited-duration bispecific antibody therapy for multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thepatientstory.com ↗
- HealthTree for Multiple Myeloma podcast/panel on FDA-approved and pipeline bispecific antibodies
sequencing, and fixed-duration treatment strategies (with Dr. Bea Razzo)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Nabila Dahodwala, MD
University of Pennsylvania
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens